Intrapleural therapy for malignant pleural effusions

A randomized comparison of bleomycin and tetracycline

J. C. Ruckdeschel, D. Moores, J. Y. Lee, Lawrence Einhorn, I. Mandelbaum, J. Koeller, G. R. Weiss, M. Losada, J. H. Keller

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.

Original languageEnglish (US)
Pages (from-to)1528-1535
Number of pages8
JournalChest
Volume100
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Bleomycin
Tetracycline
Therapeutics
Pleural Effusion
Recurrence
Drainage
Thoracostomy
Lung
Sudden Death
Embolism
Disease Progression
Arm
Thorax

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ruckdeschel, J. C., Moores, D., Lee, J. Y., Einhorn, L., Mandelbaum, I., Koeller, J., ... Keller, J. H. (1991). Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracycline. Chest, 100(6), 1528-1535.

Intrapleural therapy for malignant pleural effusions : A randomized comparison of bleomycin and tetracycline. / Ruckdeschel, J. C.; Moores, D.; Lee, J. Y.; Einhorn, Lawrence; Mandelbaum, I.; Koeller, J.; Weiss, G. R.; Losada, M.; Keller, J. H.

In: Chest, Vol. 100, No. 6, 1991, p. 1528-1535.

Research output: Contribution to journalArticle

Ruckdeschel, JC, Moores, D, Lee, JY, Einhorn, L, Mandelbaum, I, Koeller, J, Weiss, GR, Losada, M & Keller, JH 1991, 'Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracycline', Chest, vol. 100, no. 6, pp. 1528-1535.
Ruckdeschel JC, Moores D, Lee JY, Einhorn L, Mandelbaum I, Koeller J et al. Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracycline. Chest. 1991;100(6):1528-1535.
Ruckdeschel, J. C. ; Moores, D. ; Lee, J. Y. ; Einhorn, Lawrence ; Mandelbaum, I. ; Koeller, J. ; Weiss, G. R. ; Losada, M. ; Keller, J. H. / Intrapleural therapy for malignant pleural effusions : A randomized comparison of bleomycin and tetracycline. In: Chest. 1991 ; Vol. 100, No. 6. pp. 1528-1535.
@article{0f26ff3945f7467fab3139fd940008b0,
title = "Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracycline",
abstract = "Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.",
author = "Ruckdeschel, {J. C.} and D. Moores and Lee, {J. Y.} and Lawrence Einhorn and I. Mandelbaum and J. Koeller and Weiss, {G. R.} and M. Losada and Keller, {J. H.}",
year = "1991",
language = "English (US)",
volume = "100",
pages = "1528--1535",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Intrapleural therapy for malignant pleural effusions

T2 - A randomized comparison of bleomycin and tetracycline

AU - Ruckdeschel, J. C.

AU - Moores, D.

AU - Lee, J. Y.

AU - Einhorn, Lawrence

AU - Mandelbaum, I.

AU - Koeller, J.

AU - Weiss, G. R.

AU - Losada, M.

AU - Keller, J. H.

PY - 1991

Y1 - 1991

N2 - Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.

AB - Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.

UR - http://www.scopus.com/inward/record.url?scp=0026410749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026410749&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 1528

EP - 1535

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -